Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.

Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, Owiti P, Opollo V, Etard JF, Mukui I, Kim AA, Zeh C.

PLoS One. 2017 Feb 8;12(2):e0171124. doi: 10.1371/journal.pone.0171124. eCollection 2017.

2.

Human influences on evolution, and the ecological and societal consequences.

Hendry AP, Gotanda KM, Svensson EI.

Philos Trans R Soc Lond B Biol Sci. 2017 Jan 19;372(1712). pii: 20160028.

3.

The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004.

Li H, Chang S, Han Y, Zhuang D, Li L, Liu Y, Liu S, Bao Z, Zhang W, Song H, Li T, Li J.

BMC Infect Dis. 2016 Oct 26;16(1):605.

4.

A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Amano M, Salcedo-Gómez PM, Zhao R, Yedidi RS, Das D, Bulut H, Delino NS, Sheri VR, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7046-7059. Print 2016 Dec.

PMID:
27620483
5.

HIV-1 drug resistance and resistance testing.

Clutter DS, Jordan MR, Bertagnolio S, Shafer RW.

Infect Genet Evol. 2016 Dec;46:292-307. doi: 10.1016/j.meegid.2016.08.031. Epub 2016 Aug 29. Review.

PMID:
27587334
6.

Getting the Canadian HIV epidemic to zero: Valuing indigenous cultures through holistic research.

Nowgesic E.

Canadi J Aborig Community Based HIV/AIDS Res. 2013 Dec 1;5:60-70.

7.

Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery.

Soezi M, Memarnejadian A, Aminzadeh S, Zabihollahi R, Sadat SM, Amini S, Hekmat S, Aghasadeghi MR.

Rep Biochem Mol Biol. 2015 Oct;4(1):1-9.

8.

Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing.

Vrancken B, Trovão NS, Baele G, van Wijngaerden E, Vandamme AM, van Laethem K, Lemey P.

Viruses. 2016 Jan 7;8(1). pii: E12. doi: 10.3390/v8010012.

9.

Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation.

Panpradist N, Beck IA, Chung MH, Kiarie JN, Frenkel LM, Lutz BR.

PLoS One. 2016 Jan 11;11(1):e0145962. doi: 10.1371/journal.pone.0145962. eCollection 2016.

10.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DA, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CA, Schmit JC, Wensing AM; SPREAD Program..

Clin Infect Dis. 2016 Mar 1;62(5):655-63. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

11.

Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy.

Burgess MJ, Zeuli JD, Kasten MJ.

HIV AIDS (Auckl). 2015 Oct 27;7:251-64. doi: 10.2147/HIV.S39655. eCollection 2015. Review.

12.

Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.

Chauhan J, Chen SE, Fenstermacher KJ, Naser-Tavakolian A, Reingewertz T, Salmo R, Lee C, Williams E, Raje M, Sundberg E, DeStefano JJ, Freire E, Fletcher S.

Bioorg Med Chem. 2015 Nov 1;23(21):7095-109. doi: 10.1016/j.bmc.2015.09.002. Epub 2015 Sep 7.

13.

Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.

Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):228-36. doi: 10.1097/QAI.0000000000000831.

14.

In vitro antiretroviral activity and in vivo toxicity of the potential topical microbicide copper phthalocyanine sulfate.

Styczynski AR, Anwar KN, Sultana H, Ghanem A, Lurain N, Chua A, Ghassemi M, Novak RM.

Virol J. 2015 Aug 30;12:132. doi: 10.1186/s12985-015-0358-5.

15.

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Ambrosioni J, Sued O, Nicolas D, Parera M, López-Diéguez M, Romero A, Agüero F, Marcos MÁ, Manzardo C, Zamora L, Gómez-Carrillo M, Gatell JM, Pumarola T, Miró JM.

PLoS One. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837. eCollection 2015.

16.

Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds.

Yang WL, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, Scherrer AU, Shilaih M, Hinkley T, Petropoulos C, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study (SHCS)..

PLoS Pathog. 2015 Mar 23;11(3):e1004722. doi: 10.1371/journal.ppat.1004722. eCollection 2015 Mar.

17.

Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.

O'Rourke SM, Sutthent R, Phung P, Mesa KA, Frigon NL, To B, Horthongkham N, Limoli K, Wrin T, Berman PW.

PLoS One. 2015 Mar 20;10(3):e0119608. doi: 10.1371/journal.pone.0119608. eCollection 2015.

18.

Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.

Nanfack AJ, Agyingi L, Noubiap JJ, Ngai JN, Colizzi V, Nyambi PN.

J Clin Microbiol. 2015 May;53(5):1662-71. doi: 10.1128/JCM.00114-15. Epub 2015 Mar 18.

19.

Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution.

Vrancken B, Lemey P, Rambaut A, Bedford T, Longdon B, Günthard HF, Suchard MA.

Methods Ecol Evol. 2015 Jan 1;6(1):67-82.

20.

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, Johnson MA, Jacoby S, Llibre JM, Lundgren J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group..

HIV Med. 2015 Apr;16 Suppl 1:77-87. doi: 10.1111/hiv.12236.

Supplemental Content

Support Center